- Trials with a EudraCT protocol (93)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
93 result(s) found for: Independent living.
Displaying page 1 of 5.
EudraCT Number: 2005-000381-39 | Sponsor Protocol Number: KCL/DS/MEM/1 | Start Date*: 2005-08-24 |
Sponsor Name:King's College London | ||
Full Title: Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older peop... | ||
Medical condition: Cognitive decline and dementia in Down's syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023888-17 | Sponsor Protocol Number: OMS103-MEN-003 | Start Date*: 2011-05-11 | |||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic ... | |||||||||||||
Medical condition: Arthroscopic surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014424-29 | Sponsor Protocol Number: H6L-MC-LFBF (b) | Start Date*: 2010-02-05 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Open-Label Extension for Alzheimer’s Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC) | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) FR (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000502-40 | Sponsor Protocol Number: RHM CAN0380 | Start Date*: 2005-05-13 |
Sponsor Name:Southampton University Hospitals Trust | ||
Full Title: A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in "fatigue" following treatment with methylphenidate – an ex... | ||
Medical condition: Patients with cancer in palliative stage of their illness. Suffering from fatigue with or without decreased concentration, depression or drowsiness, who feel their fatigue is severe enough to decre... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000095-10 | Sponsor Protocol Number: BATCP | Start Date*: 2015-03-30 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Botulinum toxin-A as a treatment for chronic muscle-related pain in adults with spastic cerebral palsy: a randomized controlled trial. | ||
Medical condition: Spastic cerebral palsy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-017925-20 | Sponsor Protocol Number: RR08/8789 | Start Date*: 2010-09-07 | ||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||
Full Title: Does Cocareldopa treatment in combination with routine NHS occupational and physical therapy, delivered early after stroke within a stroke service, improve functional recovery including walking and... | ||||||||||||||||||
Medical condition: Ischaemic or Haemorrhagic Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001730-34 | Sponsor Protocol Number: TX200-KT02 | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:Sangamo Therapeutics France SAS | |||||||||||||
Full Title: A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Ce... | |||||||||||||
Medical condition: Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 po... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007134-19 | Sponsor Protocol Number: GAM10-04 | Start Date*: 2009-01-14 |
Sponsor Name:Octapharma AG | ||
Full Title: Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer... | ||
Medical condition: mild to moderate Alzheimer´s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002360-30 | Sponsor Protocol Number: NA-1-009 | Start Date*: 2021-01-05 | |||||||||||||||||||||||||||||||
Sponsor Name:NoNO Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Under... | |||||||||||||||||||||||||||||||||
Medical condition: Acute ischemic stroke (AIS) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) NO (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002347-41 | Sponsor Protocol Number: CA209-744 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin... | |||||||||||||
Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) Outside EU/EEA IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004719-28 | Sponsor Protocol Number: D8850C00003 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003192-19 | Sponsor Protocol Number: ISRCTN11225767 | Start Date*: 2013-02-22 | |||||||||||
Sponsor Name:London School Of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial | |||||||||||||
Medical condition: Gastrointestinal hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) RO (Completed) ES (Prematurely Ended) IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001447-43 | Sponsor Protocol Number: ALIFE2 | Start Date*: 2018-10-03 | |||||||||||
Sponsor Name:Academic Medical Center Amsterdam | |||||||||||||
Full Title: Anticoagulants for Living Fetuses in women with recurrent miscarriage and inherited thrombophilia; ALIFE2 study | |||||||||||||
Medical condition: recurrent miscarriage and inherited thrombophilia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000717-31 | Sponsor Protocol Number: WI187847 | Start Date*: 2015-06-09 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study of celecoxib after collagenase injection for adults with Dupuytren’s disease at high risk of recurrence | |||||||||||||
Medical condition: Dupuytren's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002530-20 | Sponsor Protocol Number: GEM-1802 | Start Date*: 2019-03-12 | ||||||||||||||||
Sponsor Name:Grupo Español Multidisciplinar de Melanoma | ||||||||||||||||||
Full Title: Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain. | ||||||||||||||||||
Medical condition: BRAF mutant melanoma metastatic to the brain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003753-29 | Sponsor Protocol Number: M19-148 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004209-98 | Sponsor Protocol Number: PEP 1.05 | Start Date*: 2005-12-08 |
Sponsor Name:Medical University Vienna, Department of Medicine III | ||
Full Title: The Vienna Prograf and Endothelial Progenitor Cell Study (Vienna PEP Study) | ||
Medical condition: Kidney Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006201-10 | Sponsor Protocol Number: REP0211 | Start Date*: 2012-08-13 | |||||||||||
Sponsor Name:Dompé s.p.a. | |||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation | |||||||||||||
Medical condition: Pancreatic islet transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) SE (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004946-27 | Sponsor Protocol Number: E2020-A001-219 | Start Date*: 2017-05-18 |
Sponsor Name:Eisai Inc. | ||
Full Title: A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With D... | ||
Medical condition: Down Syndrome, Cognitive Dysfunction | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
